ANDOVER, Mass.--(BUSINESS WIRE)--ndd Medical Technologies, Inc. announced that the company’s EasyOne Pro® provided highly accurate and stable pulmonary gas exchange measurements for patients across the 21 sites of the National Institutes of Health (NIH)’s COPDGene clinical trial. The COPDGene® trial chose and uses the EasyOne Pro as the exclusive DLCO testing device in the second phase of the study. More than 2,000 patients have been tested in Phase II using ndd’s advanced ultrasound-based mobile pulmonary function testing (PFT) device.
“In the COPDGene study the EasyOne Pro’s DLCO measurements have been shown to be more reproducible than any previous study to date,” said Robert Jensen, Ph.D., head of the study’s PFT Quality Assurance. “Protocols using quality assurance programs along with high precision testing instruments like the EasyOne Pro can significantly reduce variability of DLCO measurements, which allows earlier assessment of change over time for pulmonary function. These findings were presented at the 2015 ERS International Congress held in Amsterdam.”
A second presentation at ERS also showed that measurements of DLCO using the EasyOne Pro remained stable in 5,100 control subjects tested over a four-year period, without any calibration of the instrument during this time.
DLCO, a test of the diffusing capacity of the lungs, is considered to be one of the most clinically valuable tests of lung function. The easy-to-perform test measures the ability of the lungs to transfer oxygen from inhaled air to the red blood cells in pulmonary capillaries. In accordance with American Thoracic Society/European Resuscitation Society 2005 guidelines, the DLCO test entails just a single breath hold of 8-12 seconds.
“The accuracy and ease of use of our point-of-service ultrasound technology—requiring no calibration, no maintenance and no disposables other than spirettes® and barriettes® - make it the ideal tool for researchers to use to get the best possible lung-function measurements that meet testing quality standards,” said Georg Harnoncourt, CEO of ndd Medical Technologies. “The EasyOne® Plus has achieved 40 percent market-leading share in spirometry for these reasons, and our EasyOne Pro and EasyOne Pro LAB make full PFT testing available wherever the patient is—in the office, clinic, lab, hospital or at a mobile screening event.”
About ndd Medical Technologies, Inc.
With 40 percent of the U.S. spirometry market share, ndd Medical Technologies offers innovative, easy-to-use pulmonary function testing instruments that help clinicians diagnose lung disease with greater precision for optimal treatment. The EasyOne® and EasyOne Pro® portable instruments take up just 12 inches of space to take lung function testing wherever it is needed, measuring DLCO, FRC, LCI and FVC. ndd’s patented Ultrasonic TrueFlow™ technology, which requires no calibration, eliminates problems associated with traditional methods of flow measurement, making testing fast, reliable and error free. To learn more, visit www.nddmed.com.
